• Improving the Outcome of Cancer Surgery

    With our real-time imaging solutions, people fighting cancer can be confident in their treatment.

Item 1 of 3

Making cancer cells visible during surgery

Integro Theranostics is a clinical stage company developing fluorescent imaging agents and associated medical devices that enable surgeons to readily see and remove cancerous tissue. This accurate, real-time visualization of cancer tissue facilitates a more complete removal of cancer during surgery.

DID YOU KNOW?

1 in 4 people with breast cancer require repeat surgeries

DID YOU KNOW?

Black men are 11% more likely to be diagnosed with lung cancer and 10% more likely to die than white men

We use fluorescence to improve patient outcomes.

Complete removal of cancerous tumor tissue and lymph nodes is the hallmark of a successful surgery. However, surgeons have limited insight into the success of surgery while in the operating room, resulting in increased risk of cancer recurrence and a high rate of repeat surgeries.

With Integro’s fluorescent imaging agent, LS301, surgeons can easily see the amount and location of cancer cells and differentiate between healthy and cancerous tissue during surgery.

Meet Scientific Visionary Dr. Samuel Achilefu

The inventor of Integro’s revolutionary technologies is a pioneering expert in the design and use of fluorescent molecules to improve cancer imaging.

Committed to Addressing Health Disparities

Our product development priorities are informed by our commitment to improving disparities in cancer treatment and patient outcomes. Inadequate health insurance, poor access to high-quality detection and treatment, and lack of diversity in clinical trials are just some of the myriad of factors that contribute to cancer health disparities. Integro is committed to developing products that are accessible to all patients and in establishing partnerships to pursue cancer health equity.

Interested in partnering to improve treatment for all cancer patients?